Who are di indolylmethane (DIM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Orserdu, Nextstellis, Cerianna, Duavee, Osphena, Duavee.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/di-indolylmethane-dim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

di indolylmethane (DIM) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

di indolylmethane (DIM) (di indolylmethane (DIM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Indole. Area: Oncology.

phase 3 Indole Estrogen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

di indolylmethane (DIM) (di indolylmethane (DIM)) — New York Presbyterian Hospital. DIM is a natural compound that acts as an estrogen receptor antagonist and a weak estrogen receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
di indolylmethane (DIM) TARGET	di indolylmethane (DIM)	New York Presbyterian Hospital	phase 3	Indole	Estrogen receptor
Orserdu	ELACESTRANT	Stemline Therap	marketed	Estrogen Receptor Antagonist [EPC]	Estrogen receptor	2023-01-01
Nextstellis	ESTETROL	Mayne Pharma	marketed	Estrogen	Estrogen receptor	2021-01-01
Cerianna	FLUOROESTRADIOL F-18	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Estrogen receptor	2020-01-01
Duavee	conjugated-estrogens-bazedoxifene	Pfizer	marketed	Estrogen [EPC]	estrogen receptors α and β	2013-01-01
Osphena	OSPEMIFENE	Duchesnay	marketed	Estrogen Agonist/Antagonist [EPC]	Estrogen receptor beta	2013-01-01
Duavee	BAZEDOXIFENE	Wyeth Pharms Pfizer	marketed	Estrogen [EPC]	estrogen receptors (ER) α and β	2013-01-01

Recent regulatory actions (last 90 days)

2026-03-26 — Nextstellis · EMA · approved · EU · Mayne Pharma

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-03-10 — Duavee · 7683051 · US

Sponsor landscape (Indole class)

New York Presbyterian Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). di indolylmethane (DIM) — Competitive Intelligence Brief. https://druglandscape.com/ci/di-indolylmethane-dim. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing